Fredun Pharmaceuticals Ltd. (FREDUN): Fredun Pharmaceuticals Share Price Rises 9.55% Today

Fredun Pharmaceuticals shares traded at Rs 1,398, up 9.55% today, taking its market capitalisation to Rs 2,014.34 crore and placing the small-cap stock in focus on BSE.

Fredun Pharmaceuticals Share Price moved up sharply in today’s session, with the stock trading at Rs 1,398, higher by Rs 121.9 or 9.55%. At this level, the company’s market capitalisation stood at Rs 2,014.34 crore, bringing the small-cap pharmaceutical stock into focus in Stock Market Today and among market movers on BSE.

For readers tracking Fredun Pharmaceuticals Share Price Today, the verified data confirms a strong same-day price rise rather than a long-term milestone event. The stock opened at Rs 1,293.7, moved within a session range of Rs 1,270 to Rs 1,400, and recorded turnover of Rs 5.12 crore on 36,642 shares on BSE. That combination of price movement and participation is what makes this Fredun Pharmaceuticals Stock News item relevant in today’s Share Market Today.

The supplied data confirms what happened in the market, but it does not establish a company-specific catalyst for why the stock is rising today. Even so, Fredun Pharmaceuticals Share Price is trending because the size of the move was large enough to qualify under the workflow’s price-rise screen for its market-cap bucket, making it one of the Stocks in News for the session.

From a financial perspective, investors are also looking at valuation and profitability markers. Fredun Pharmaceuticals has a P/E ratio of 48.16, a P/B ratio of 7.19, ROE of 11.42, ROCE of 13.15, EPS of 26.5 and dividend yield of 0.02. On Univest, that creates a useful framework: today’s price action is clear, the catalyst is not verified by the supplied data, and the next things to monitor are whether volume participation remains active, how valuation compares with peers, and where the stock sits within the broader Healthcare and Pharmaceuticals & Drugs universe.

Fredun Pharmaceuticals Ltd. (FREDUN) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,398
Previous Close	Rs 1,276.1
Today's Change	+Rs 121.9 (+9.55%)
Day Open	Rs 1,293.7
Day High	Rs 1,400
Day Low	Rs 1,270
Current Volume (BSE)	36,642
BSE Traded Volume	36,642
Combined NSE + BSE Volume	36,642
Turnover	Rs 5.12 crore
Market Capitalisation	Rs 2,014.34 crore
Market Cap Category	Small Cap

Fredun Pharmaceuticals Ltd. (FREDUN) traded at Rs 1,398. versus the previous close of Rs 1,276.1, a rise of 9.55%. The stock opened at Rs 1,293.7, reached Rs 1,400, touched Rs 1,270. Reported volume was 36,642.

Fredun Pharmaceuticals Ltd. (FREDUN) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 2,014.34 crore
P/E Ratio	48.16x
P/B Ratio	7.19x
ROE	11.42%
ROCE	13.15%
EPS	Rs 26.5
Dividend Yield	0.02%

Fredun Pharmaceuticals Ltd. was valued at a P/E ratio of 48.16x, a P/B ratio of 7.19x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 11.42% and ROCE of 13.15%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 26.5, dividend yield of 0.02%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Fredun Pharmaceuticals Fundamental Analysis begins with a clear contrast between strong market attention and a valuation profile that already embeds meaningful expectations. With a market cap of Rs 2,014.34 crore, the company sits in the small-cap bracket, which indicates size but not necessarily quality. The more revealing metrics are its earnings and balance-sheet multiples, along with profitability ratios.

The stock is trading at a P/E ratio of 48.16 and a P/B ratio of 7.19. Those are not low headline valuations in absolute terms, and they suggest that the market is assigning a relatively rich multiple to the company’s reported earnings and book value. EPS stands at 26.5, which indicates the earnings attributable to each share. When paired with a share price of Rs 1,398, that EPS level is what underpins the current P/E multiple. Book value per share is reflected through the P/B ratio rather than a separately supplied book value figure, and the multiple of 7.19 shows the market price is several times the accounting net worth carried on the balance sheet.

Profitability is moderate rather than extreme. ROE is 11.42, showing the return generated on shareholder equity, while ROCE is 13.15, showing the return earned on capital employed across the business. These are positive and relevant figures, but they do not by themselves point to unusually high profitability relative to every peer in the listed pharmaceuticals space.

Dividend yield is 0.02, which is a very low historical/current payout relative to the prevailing share price. That means the Fredun Pharmaceuticals Share Price story today is not about income appeal; it is more about market re-rating, earnings valuation and stock performance. For Univest readers following Fredun Pharmaceuticals Stock Analysis, the key takeaway is that the stock’s rise is happening against a backdrop of premium valuation ratios and mid-range profitability metrics, which makes sector benchmarking essential before drawing broader conclusions.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	48.16x
Benchmark Median P/E	24.45x
Benchmark Average P/E	79.31x
Benchmark P/E Range	3.31x to 3,374.81x
Company P/B Ratio	7.19x
Benchmark Median P/B	1.82x
Company ROE	11.42%
Benchmark Median ROE	10.49%
Company ROCE	13.15%
Benchmark Median ROCE	12.97%
Company Market Capitalisation	Rs 2,014.34 crore
Benchmark Median Market Cap	Rs 146.94 crore

Fredun Pharmaceuticals Ltd. (FREDUN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Fredun Pharmaceuticals Ltd. (FREDUN) has a P/E ratio of 48.16x, which is above the benchmark median of 24.45x, a difference of +96.97%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Fredun Pharmaceuticals Ltd. (FREDUN) has a ROE of 11.42%, which is above the benchmark median of 10.49%, a difference of +8.87%. Fredun Pharmaceuticals Ltd. (FREDUN) has a ROCE of 13.15%, which is above the benchmark median of 12.97%, a difference of +1.39%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Fredun Pharmaceuticals operates in Healthcare, specifically the Pharmaceuticals & Drugs industry. Against the supplied same-industry benchmark of 136 companies, the stock’s valuation and profitability metrics place it in an interesting middle ground: pricier than the median on valuation, but not uniformly stronger than the full peer set on returns.

The benchmark scope here is explicitly the same industry, covering 136 companies. Fredun Pharmaceuticals’ company P/E is 48.16. That is above the industry median P/E of 24.45, but below the industry average P/E of 79.31. The wide range of industry valuations is important: the minimum P/E is 3.31 while the maximum is 3,374.81 across 104 companies with available P/E data. That tells Univest readers the pharmaceuticals basket contains both low-multiple names and very highly valued outliers, so the company’s multiple is elevated versus the median but still well below the most aggressively priced counters.

On price-to-book, Fredun’s P/B of 7.19 is materially above the industry median of 1.82 and the industry average of 2.46 across 135 companies. The industry range runs from -16.74 to 16.32, but even within that spread, 7.19 stands out as a relatively high valuation multiple. That means Fredun Pharmaceuticals Share Price is carrying a stronger balance-sheet premium than many industry peers.

Profitability is more balanced. Company ROE of 11.42 is above the industry median ROE of 10.49 and above the average of 8.1. Company ROCE of 13.15 is slightly above the industry median ROCE of 12.97, though below the average ROCE of 15.64. Market-cap context also matters: Fredun’s Rs 2,014.34 crore market capitalisation is far above the benchmark median of Rs 146.94 crore and above the average of Rs 484.32 crore, though below the industry maximum of Rs 2,949.87 crore. In sector terms, this is not a tiny niche listing; it is already among the larger names within its same-industry benchmark set.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,949.87	31.07	0.45	-2.89	-0.26
Beta Drugs Ltd.	BETA	2,775.9	71.31	11.28	18.65	22.17
Hikal Ltd.	HIKAL	2,761.32	0	2.26	15.22	16.15
Sai Parenteral's Ltd.	SAIPARENT	2,594.65	179.52	3.32	13.9	12.97
Solara Active Pharma Sciences Ltd.	SOLARA	2,474.65	0	1.92	17.23	15.34

Fredun Pharmaceuticals Ltd. (FREDUN) has a P/E ratio of 48.16x compared with the displayed peer median of 31.07x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.42% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 13.15% versus the displayed peer median of 15.34%, providing a capital-efficiency comparison. Fredun Pharmaceuticals Ltd. (FREDUN) has a market capitalisation of Rs 2,014.34 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Fredun Pharmaceuticals compares with listed Pharmaceuticals & Drugs peers as a mid-to-upper market-cap name in this benchmark group, but its valuation and return profile is mixed rather than clearly dominant. That is important for investors looking beyond today’s gain and trying to place the company within a wider peer framework.

Starting with market capitalisation, Fredun Pharmaceuticals at Rs 2,014.34 crore is smaller than Dishman Carbogen Amcis Ltd. at Rs 2,949.87 crore, Beta Drugs Ltd. at Rs 2,775.9 crore and Hikal Ltd. at Rs 2,761.32 crore. It is also below Sai Parenteral’s Ltd. at Rs 2,594.65 crore and Solara Active Pharma Sciences Ltd. at Rs 2,474.65 crore. However, it remains in the same broad size band as NGL Fine-Chem Ltd. at Rs 2,140.53 crore, Hester Biosciences Ltd. at Rs 2,128.33 crore, Ind-Swift Laboratories Ltd. at Rs 2,061.86 crore and Indoco Remedies Ltd. at Rs 2,038.53 crore.

On valuation, Fredun’s P/E of 48.16 is higher than Dishman Carbogen Amcis at 31.07, NGL Fine-Chem at 44.41, Hester Biosciences at 15.51 and Ind-Swift Laboratories at 43.16. It is lower than Beta Drugs at 71.31, Sai Parenteral’s at 179.52 and Indoco Remedies at 355.2. This places Fredun Pharmaceuticals Share Price in a premium but not extreme earnings-multiple bracket within its peer set.

The P/B ratio of 7.19 is also elevated. It is above Dishman’s 0.45, Hikal’s 2.26, Sai Parenteral’s 3.32, Solara’s 1.92, Panacea Biotec’s 2.95, Hester’s 4.64 and Ind-Swift’s 1.65, though below Beta Drugs’ 11.28. It is modestly above NGL Fine-Chem’s 6.49 as well.

Profitability comparisons are similarly mixed. Fredun’s ROE of 11.42 is stronger than Dishman’s -2.89, Panacea Biotec’s 0 and Ind-Swift’s -0.78, but lower than Beta Drugs’ 18.65, Hikal’s 15.22, Sai Parenteral’s 13.9, Solara’s 17.23, NGL Fine-Chem’s 27.9, Hester’s 16.17 and Indoco’s 12.85. ROCE of 13.15 is above Dishman’s -0.26, Panacea’s 5.36 and Ind-Swift’s 8.31, nearly in line with Sai Parenteral’s 12.97, but below Beta Drugs’ 22.17, Hikal’s 16.15, Solara’s 15.34, NGL Fine-Chem’s 33.91, Hester’s 14.12 and Indoco’s 15.67. For Univest, that means the stock’s current re-rating is supported more by market pricing than by obvious peer-leading return metrics.

Why Investors Are Watching Fredun Pharmaceuticals

Fredun Pharmaceuticals is being watched because today’s share price rise was large enough to move it onto active market screens, while its valuation and peer data create a more layered stock analysis story than a simple intraday move. The stock is also part of the Healthcare sector, a space where investors regularly compare valuation premiums against return ratios and market-cap positioning.

• Verified price action: Fredun Pharmaceuticals Share Price rose 9.55% to Rs 1,398 from Rs 1,276.1, with an intraday high of Rs 1,400 and turnover of Rs 5.12 crore.
• Market position: The company’s market capitalisation of Rs 2,014.34 crore places it in the Small Cap category and among notable Stocks in News for the session.
• Valuation context: P/E of 48.16 and P/B of 7.19 are above the industry median levels of 24.45 and 1.82 respectively.
• Profitability context: ROE of 11.42 is above the industry median of 10.49, while ROCE of 13.15 is slightly above the median of 12.97.
• Peer positioning: The company is in a comparable market-cap band with names such as NGL Fine-Chem, Hester Biosciences, Ind-Swift Laboratories and Indoco Remedies.

What investors may monitor next is whether Fredun Pharmaceuticals Share Price continues to hold near the upper end of its recent trading range, whether trading value remains active after today’s move, and how the stock’s premium valuation behaves relative to peers with stronger or weaker return ratios. On Univest, this becomes a watchlist name because price action is strong, while the fundamental picture is more nuanced.

About Fredun Pharmaceuticals

Fredun Pharmaceuticals Ltd. is classified within the Healthcare sector and the Pharmaceuticals & Drugs industry. Based on the supplied company context, the stock sits inside a broad listed pharmaceutical universe that includes formulation, drug and healthcare-focused businesses of varying scale, valuation and profitability.

In market terms, Fredun Pharmaceuticals is not a micro listing inside this industry basket. Its market capitalisation of Rs 2,014.34 crore is well above the same-industry median market cap of Rs 146.94 crore and the average of Rs 484.32 crore, which indicates that it is already one of the larger listed companies in this benchmark universe. That scale can matter because investors often compare similarly sized healthcare names on P/E, P/B, ROE and ROCE before drawing conclusions from a single session of price action.

The company’s positioning inside Pharmaceuticals & Drugs also matters because the industry itself shows wide dispersion in valuation and profitability. Some peers trade at low multiples with weak returns, while others command high valuations with stronger returns. Fredun Pharmaceuticals currently sits somewhere in between those extremes. For readers following Fredun Pharmaceuticals Share News and Fredun Pharmaceuticals Latest News, that makes the stock relevant not only because it rose today, but because its numbers place it in an active and highly differentiated part of the Indian Stock Market.

Track Fredun Pharmaceuticals Share Price on Univest

Use Fredun Pharmaceuticals Ltd. (FREDUN) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors who want to follow Fredun Pharmaceuticals Share Price more closely can track the stock on Univest for live share price updates, market-cap changes, valuation ratios and broader stock analysis. Univest also helps users monitor indicators such as price action, 52-week levels, peer comparison metrics, sector benchmarks and company financial ratios in one place.

For traders and long-term market participants alike, Fredun Pharmaceuticals Share Price Today is more useful when viewed alongside P/E, P/B, ROE, ROCE, EPS, dividend yield and industry context rather than in isolation. Univest makes that comparison-driven view easier, especially when a stock becomes one of the day’s notable market movers on BSE and enters active investor screens through verified stock updates.

Frequently Asked Questions

Why did Fredun Pharmaceuticals Share Price rise today?

Ans. Fredun Pharmaceuticals Share Price rose because the market recorded a strong same-day gain of 9.55%, taking the stock to Rs 1,398 from the previous close of Rs 1,276.1. The supplied data confirms the move, but does not establish a company-specific.

What is Fredun Pharmaceuticals Share Price Today?

Ans. Fredun Pharmaceuticals Share Price Today was Rs 1,398 at the time of the article. That represented a gain of Rs 121.9, or 9.55%, for the session, placing the stock among notable BSE gainers in today’s market update.

What were the day high, day low and opening price of Fredun Pharmaceuticals shares?

Ans. The stock opened at Rs 1,293.7, touched a day high of Rs 1,400 and a day low of Rs 1,270. This shows a wide intraday range, with the share price trading close to the session high later in the day.

How much trading activity was seen in Fredun Pharmaceuticals today?

Ans. Fredun Pharmaceuticals recorded volume of 36,642 shares on BSE, which was also the reported total volume for the session. Turnover stood at Rs 5.12 crore, showing that today’s price rise came with meaningful traded value.

What is the market capitalisation of Fredun Pharmaceuticals?

Ans. Fredun Pharmaceuticals had a market capitalisation of Rs 2,014.34 crore at the time of writing. That places the company in the Small Cap category and makes today’s 9.55% move especially visible on market screens tracking active gainers.

Is Fredun Pharmaceuticals expensive compared with its industry on P/E?

Ans. The company’s P/E ratio is 48.16, which is above the same-industry median of 24.45 but below the industry average of 79.31. That suggests a premium valuation versus the median, though not the highest pricing seen in the sector.

How does Fredun Pharmaceuticals compare with the industry on P/B?

Ans. Fredun Pharmaceuticals has a P/B ratio of 7.19, higher than the industry median of 1.82 and the average of 2.46. This indicates the stock trades at a stronger balance-sheet premium than many listed Pharmaceuticals & Drugs peers.

What do ROE and ROCE show for Fredun Pharmaceuticals?

Ans. ROE stands at 11.42 and ROCE at 13.15. ROE is above the industry median of 10.49, while ROCE is slightly above the industry median of 12.97, indicating respectable but not peer-leading profitability in the supplied comparison set.

What are the EPS and dividend yield of Fredun Pharmaceuticals?

Ans. Fredun Pharmaceuticals reported EPS of 26.5 and dividend yield of 0.02 in the supplied data. EPS reflects earnings attributable to each share, while the very low dividend yield suggests the stock is not currently an income-focused story.

Which peers are relevant when comparing Fredun Pharmaceuticals?

Ans. Relevant listed peers in the supplied Pharmaceuticals & Drugs set include Beta Drugs, Hikal, NGL Fine-Chem, Hester Biosciences and Indoco Remedies. These companies help frame Fredun’s market-cap position, valuation multiples and profitability against similarly tracked healthcare stocks.